INDIGO: A global, randomized, double-blind, phase 3 study of vorasidenib (AG-881) vs placebo in patients with residual/recurrent grade II glioma with an isocitrate dehydrogenase 1/2 (IDH1/2) mutation Meeting Abstract
| Authors: | Mellinghoff, I.; van den Bent, M.; Clarke, J.; Maher, E.; Peters, K.; Touat, M.; de Groot, J.; De La Fuente, M.; Arrillaga-Romany, I.; Wick, W.; Ellingson, B.; Schoenfeld, S.; Liu, H.; Le, K.; Lu, M.; Steelman, L.; Hassan, I.; Pandya, S.; Wen, P.; Cloughesy, T. |
| Abstract Title: | INDIGO: A global, randomized, double-blind, phase 3 study of vorasidenib (AG-881) vs placebo in patients with residual/recurrent grade II glioma with an isocitrate dehydrogenase 1/2 (IDH1/2) mutation |
| Meeting Title: | 25th Virtual Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology |
| Journal Title: | Neuro-Oncology |
| Volume: | 22 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2020 Nov 19-21 |
| Meeting Location: | Virtual |
| ISSN: | 1522-8517 |
| Publisher: | Oxford University Press |
| Date Published: | 2020-11-01 |
| Start Page: | ii194 |
| Language: | English |
| ACCESSION: | WOS:000590061300811 |
| PROVIDER: | wos |
| DOI: | 10.1093/neuonc/noaa215.810 |
| Notes: | Meeting Abstract: RTID-05 -- Source: Wos |
